drugset / Trial / NCT01324934
Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
Phase 3
Terminated
40 enrolled
Neovii Biotech
Eurotrials Brasil Consultores Cientificos Ltda · collabPsyConsult · collabRecerca Clínica S.L. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of the study is the assessment of the overall graft rejection rate (acute, chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to standard treatment consisting of CellCept® or Myfortic®/TAC and without corticosteroids and a treatment consisting of CellCept® or Myfortic®/TAC and corticosteroids during the first year after renal transplantation.
Timeline
- Start
- 2006-10
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Thymoglobulin | Protein / enzyme biologic | 3 mg/kg | — |